相关实验视频

Updated: May 27, 2025

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

用重复低剂量的MDMA治疗神经病痛:一个案例报告

Peter Gasser¹, Matthias E Liechti², Friederike Holze²

¹Private Practitioner, Solothurn, Switzerland.

Frontiers in psychiatry

|February 18, 2025

概括

本案例研究探讨了使用lysergic acid diethylamide (LSD) 和methylenedioxymethamphetamine (MDMA) 治疗神经病痛的方法. 低剂量的MDMA显示在疼痛管理中持续改善.

科学领域:

心理药理学心理药理学
神经学神经学
在瘤学瘤学.

背景情况:

神经病痛是一种使人衰弱的疾病,通常与癌症化疗有关.
创伤性生活经历可以加剧疼痛感知和治疗结果.
关于迷幻药物和共情药物在疼痛管理中的治疗潜力,研究有限.

研究的目的:

研究 lysergic acid diethylamide (LSD) 和甲基二氧化甲胺 (MDMA) 对患有创伤史的患者的神经病痛的作用.
探索MDMA高剂量和微剂量管理的疗效,以缓解疼痛.
为了记录MDMA治疗后持续疼痛改善的情况.

主要方法:

一名64岁的男性患者患有化疗诱导的神经病痛和创伤史,接受了不断升级的LSD剂量 (200微克,然后400微克).
在LSD治疗后,患者服用高剂量 (150-175毫克) 和微剂量 (12.5-25毫克) 的MDMA.
在整个治疗过程中,对主观效应和持久的治疗效益,特别是疼痛减轻,进行了监测.

主要成果:

200μg的LSD没有产生急性主观效应,而400μg产生急性效应和初始治疗效益.
高剂量和微剂量MDMA的使用都导致神经病痛的明显改善.
观察到的疼痛缓解甚至在停止重复的MDMA治疗后也持续存在.

结论:

这一案例表明,MDMA,包括低剂量 (微剂量),可能为神经病痛提供一个可行的治疗选择.
需要进一步的临床研究来调查MDMA在疼痛障碍中的疗效和机制.
这些发现强调了新型药理干预措施在管理复杂疼痛疾病方面的潜力.

关键词:

这是一种LSD,一种LSD.这是MDMA,MDMA.慢性疼痛是一种慢性疼痛.有限制的医疗用途.微量注射是一种微量注射.迷幻药物辅助疗法迷幻药物辅助疗法

更多相关视频

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

相关概念视频

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

CNS Stimulants: Psychedelic Agents

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...